Development of the Drug and Alcohol Respiratory Health Test

NCT06921278 | Not Yet Recruiting

• 1 other identifier: DARHT
• Study Type: observational
• Target: 260
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to develop a brief Drug and Alcohol Respiratory Health Test (DARHT) and offer it for routine use in clinical assessment and medical reviews

Conditions

Respiratory Disease; Substance-Related Disorders; COPD; Asthma; Lung Cancer; Tuberculosis; Bronchitis; Pneumonia; Obstructive Sleep Apnea

Outcome Measures

Primary Outcomes (1)

• A brief respiratory health screening questionnaire

  To investigate the accuracy of a brief respiratory health screening questionnaire in highlighting respiratory health symptoms in participants with Substance Use Disorders.

  Day 1 and Day 3-7

Secondary Outcomes (1)

• Specialist nurse and psychology assistant delivered Lung Health Clinic

  Week 1 to Week 6

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Addictions Community Centre for those suffering from substance-related disorders who may also have underlying respiratory diseases.

You may qualify if:

• \>18 (no upper age limit)
• Inhalation (smoking) of tobacco, or cannabis, or cocaine, or opioids, or use of alcohol in the past 28 days
• Possession of a personal mobile phone to arrange follow-up appointments

You may not qualify if:

• Reported physical health condition that would mean spirometry contra-indicated - including heart attack, unstable angina, pulmonary embolism,
• Reported surgery in the past 3 months for an eye, chest, or abdominal condition that would mean spirometry contra-indicated
• Likely inability to complete study due to criminal justice involvement with legal proceedings risking incarceration

Sponsors & Collaborators

• King's College London: lead
• South London and Maudsley NHS Foundation Trust: collaborator

Study Sites (1)

South London & Maudsley NHS Trust

London, BR3 3BX, United Kingdom

Location

MeSH Terms

Conditions

Respiration Disorders; Substance-Related Disorders; Pulmonary Disease, Chronic Obstructive; Asthma; Lung Neoplasms; Tuberculosis; Bronchitis; Pneumonia; Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Respiratory Tract Diseases; Chemically-Induced Disorders; Mental Disorders; Lung Diseases, Obstructive; Lung Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Bronchial Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Mycobacterium Infections; Actinomycetales Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Respiratory Tract Infections; Sleep Apnea Syndromes; Apnea; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases

Central Study Contacts

John Marsden, B.Sc., M.Sc., PhD, PgDiP CBT

CONTACT

+44 02078365454; john.marsden@kcl.ac.uk

Francesca Small, Msc

CONTACT

+ 44 020 3228 1500; francesca.a.small@kcl.ac.uk

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 21, 2025
• First Posted: April 10, 2025
• Study Start: April 15, 2025
• Primary Completion: November 11, 2025
• Study Completion: November 11, 2025
• Last Updated: April 10, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)